"目录号: HY-14605
Rasagiline甲磺酸盐是MAO-B抑制剂，可作用于原发性帕金森病。
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-BRasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3].
Clinical Trial
Chongqing Fortune Pharmaceutical Co., Ltd.-Beijing Bionovo Medicine Development Co., Ltd.
Parkinson´s Disease
November 2011
Phase 3
Teva Pharmaceutical Industries
Parkinson's Disease
June 2013
Phase 1
Teva Pharmaceutical Industries
Parkinson's Disease
May 2002
Phase 3
Technische Universität Dresden-Teva Pharmaceutical Industries
Sleep Disturbances-Parkinsons's Disease
October 2011
Phase 4
H. Lundbeck A/S
Parkinson's Disease
May 2012
Phase 1
Richard Barohn, MD-University of Kansas Medical Center
Amyotrophic Lateral Sclerosis (ALS)
September 2012
Phase 2
Teva Pharmaceutical Industries-Teva Neuroscience, Inc.-H. Lundbeck A/S
Parkinson's Disease
July 2009
University of Florida
Parkinson's Disease
December 2009
Phase 4
Teva Pharmaceutical Industries
Parkinson's Disease
December 2009
Phase 4
Teva Pharmaceutical Industries
Parkinson's Disease
October 2001
Phase 3
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Parkinson's Disease
September 2008
Phase 4
University of Zurich-H. Lundbeck A/S
Parkinson's Disease
September 2011
Phase 4
University of Ulm
Amyotrophic Lateral Sclerosis
June 2013
Phase 2
University of Virginia-Teva Neuroscience, Inc.
Restless Legs Syndrome
September 2010
Phase 2-Phase 3
Teva Branded Pharmaceutical Products, R&D Inc.-Teva Pharmaceutical Industries
Parkinson's Disease
November 2012
Phase 4
Teva Pharmaceutical Industries-H. Lundbeck A/S
Multiple System Atrophy
December 2009
Phase 2
H. Lundbeck A/S
Parkinson's Disease
April 2012
Phase 3
Istanbul University
Parkinson's Disease
June 2007
Phase 4
The Parkinson's Institute-Teva Neuroscience, Inc.
Parkinson's Disease
November 2009
Phase 4
Yunxia Wang, MD-Western ALS Study Group-University of Kansas Medical Center
Amyotrophic Lateral Sclerosis (ALS)
December 2011
Phase 2
University of Maryland-Stanley Medical Research Institute
Schizophrenia
January 2007
Phase 4
Teva Neuroscience, Inc.-H. Lundbeck A/S-Teva Pharmaceutical Industries
Parkinson's Disease
December 2009
Phase 4
Bial - Portela C S.A.
Parkinson Disease
November 2009
Phase 1
Lundbeck Italia S.p.A.-Teva Pharmaceutical Industries
Depressive Symptoms-Parkinson's Disease
March 2010
Phase 4
Thomas Guttuso-University at Buffalo
Parkinson's Disease
November 2014
University Hospital Inselspital, Berne
Retinal Detachment
September 2010
Phase 4
Georgetown University-Teva Neuroscience, Inc.
Parkinson's Disease
January 2012
Phase 4
Teva Pharmaceutical Industries
Serotonin Syndrome
July 2009
The Cleveland Clinic
Alzheimer's Disease
May 2015
Phase 2
Brown University-Teva Pharmaceuticals USA
Parkinson's Disease
June 2011
Phase 4
Prof. Dr. Stefan Lorenzl-Teva Pharmaceutical Industries-Ludwig-Maximilians - University of Munich
Progressive Supranuclear Palsy
January 2010
Phase 3
St. Josef Hospital Bochum
Parkinson Disease
October 2011
Phase 4
Teva Pharmaceutical Industries
Parkinson's Disease
November 2005
Phase 3
Bial - Portela C S.A.
Parkinson Disease
November 2009
Phase 1
Qualissima-H. Lundbeck A/S
Early-stage Parkinson's Disease
October 2008
Phase 4
Teva Pharmaceutical Industries
Parkinson's Disease
May 2000
Phase 3
Teva Neuroscience, Inc.-Teva Pharmaceutical Industries
Parkinson's Disease
October 2006
Phase 4
Teva Pharmaceutical Industries
Parkinson's Disease
June 2004
Phase 3
Teva Pharmaceutical Industries-Eisai Inc.
Dementia-Alzheimer's Disease
August 2004
Phase 2
Teva Neuroscience, Inc.-Teva Pharmaceutical Industries
Parkinson's Disease
July 1997
Phase 3
University of Florida-National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
December 2016
Pharma Two B Ltd.
Parkinson's Disease
December 2013
Phase 2-Phase 3
Merck Sharp & Dohme Corp.
Parkinson Disease-Idiopathic Parkinson Disease
November 2010
Phase 3
Teva Pharmaceutical Industries
Parkinson's Disease
October 2000
Phase 3
Merck Sharp & Dohme Corp.
Parkinson Disease
July 2010
Phase 3
Merck Sharp & Dohme Corp.
Parkinson Disease
July 14, 2010
Phase 3
View MoreCollapse
References
